Hexokinase-2 Expression in 11C-Methionine-Positive, 18F-FDG-Negative Multiple Myeloma
© 2019 by the Society of Nuclear Medicine and Molecular Imaging..
PET with 18F-FDG is the standard modality in nuclear medicine for imaging multiple myeloma (MM). However, viable MM as detected by MRI or PET with other metabolic tracers, including 11C-methionine, may be missed-for example, because of low hexokinase 2 (HK2) expression of tumor cells. The aim of this study was to further investigate potential reasons for PET false negativity. Methods: A cohort of 15 mainly pretreated patients with relapsed or refractory biopsy-proven, serologically active MM who underwent both 18F-FDG and 11C-methionine PET/CT was retrospectively analyzed. Results: In 9 of the 15 patients, 18F-FDG PET was negative in the presence of viable disease. In the remaining 6 patients, both 18F-FDG and 11C-methionine PET/CT revealed the same number of MM lesions. At immunohistochemistry, 18F-FDG-negative myeloma did not exhibit significant differences in HK2 or glucose-6-phosphatase expression from 18F-FDG-positive disease (P = 0.57 and P = 0.44, respectively). Conclusion: Beyond HK2 expression, 18F-FDG negativity in (mainly pretreated) MM patients seems to be associated with additional causes not yet known.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 60(2019), 3 vom: 02. März, Seite 348-352 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kircher, Stefan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0Z5B2CJX4D |
|---|
| Anmerkungen: |
Date Completed 25.10.2019 Date Revised 25.10.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2967/jnumed.118.217539 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM290231736 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM290231736 | ||
| 003 | DE-627 | ||
| 005 | 20231225064302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2967/jnumed.118.217539 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0967.xml |
| 035 | |a (DE-627)NLM290231736 | ||
| 035 | |a (NLM)30389821 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kircher, Stefan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hexokinase-2 Expression in 11C-Methionine-Positive, 18F-FDG-Negative Multiple Myeloma |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.10.2019 | ||
| 500 | |a Date Revised 25.10.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 by the Society of Nuclear Medicine and Molecular Imaging. | ||
| 520 | |a PET with 18F-FDG is the standard modality in nuclear medicine for imaging multiple myeloma (MM). However, viable MM as detected by MRI or PET with other metabolic tracers, including 11C-methionine, may be missed-for example, because of low hexokinase 2 (HK2) expression of tumor cells. The aim of this study was to further investigate potential reasons for PET false negativity. Methods: A cohort of 15 mainly pretreated patients with relapsed or refractory biopsy-proven, serologically active MM who underwent both 18F-FDG and 11C-methionine PET/CT was retrospectively analyzed. Results: In 9 of the 15 patients, 18F-FDG PET was negative in the presence of viable disease. In the remaining 6 patients, both 18F-FDG and 11C-methionine PET/CT revealed the same number of MM lesions. At immunohistochemistry, 18F-FDG-negative myeloma did not exhibit significant differences in HK2 or glucose-6-phosphatase expression from 18F-FDG-positive disease (P = 0.57 and P = 0.44, respectively). Conclusion: Beyond HK2 expression, 18F-FDG negativity in (mainly pretreated) MM patients seems to be associated with additional causes not yet known | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 11C-methionine | |
| 650 | 4 | |a 18F-FDG | |
| 650 | 4 | |a PET/CT | |
| 650 | 4 | |a glucose-6-phosphatase | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 7 | |a Carbon Radioisotopes |2 NLM | |
| 650 | 7 | |a Carbon-11 |2 NLM | |
| 650 | 7 | |a Fluorodeoxyglucose F18 |2 NLM | |
| 650 | 7 | |a 0Z5B2CJX4D |2 NLM | |
| 650 | 7 | |a Methionine |2 NLM | |
| 650 | 7 | |a AE28F7PNPL |2 NLM | |
| 650 | 7 | |a Hexokinase |2 NLM | |
| 650 | 7 | |a EC 2.7.1.1 |2 NLM | |
| 700 | 1 | |a Stolzenburg, Antje |e verfasserin |4 aut | |
| 700 | 1 | |a Kortüm, Klaus Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Kircher, Malte |e verfasserin |4 aut | |
| 700 | 1 | |a Da Via, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Samnick, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Buck, Andreas K |e verfasserin |4 aut | |
| 700 | 1 | |a Einsele, Hermann |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenwald, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Lapa, Constantin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nuclear medicine : official publication, Society of Nuclear Medicine |d 1960 |g 60(2019), 3 vom: 02. März, Seite 348-352 |w (DE-627)NLM000042072 |x 1535-5667 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2019 |g number:3 |g day:02 |g month:03 |g pages:348-352 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2967/jnumed.118.217539 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2019 |e 3 |b 02 |c 03 |h 348-352 | ||